
Health NCP Net

InfoDay Cluster 1 “Health”

ANNEX 1: Q&A on new Calls 2024

www.healthncp.net



HNN3.0 (The Cluster 1 Health consortium of NCPs for Horizon Europe) has received funding from the European Union's Horizon EUROPE research and innovation programme under Grant Agreement number 101057279

This Annex 1 complements the “InfoDay Cluster 1 Health Q&A on Calls 2024”, developed by the project Health-NCP-Net 3.0 (HNN 3.0). On May 28th, 2024, a virtual [Horizon Info Day](#) was organized by the European Commission for the three new topics that have been added to the Cluster 1 ‘Health’ work programme of 2024.

The European Commission has published the slides and videos of the topic presentations and the questions and answers (Q&A) online.

This document prepared by NCPs will give you the links to all topic presentations and Q&A sessions including the exact time in the video where the questions are answered.

CONTENTS

[Destination 3: Tackling diseases and reducing disease burden](#)..... 3

- HORIZON-HLTH-2024-DISEASE-13-01: Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)
- HORIZON-HLTH-2024-DISEASE-12-01: European partnership for pandemic preparedness

[Destination 4: Ensuring access to innovative, sustainable and high-quality health care](#)..... 4

- HORIZON-HLTH-2024-CARE-14-01: Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems (PCP)

Destination 3. Tackling diseases and reducing disease burden

HORIZON-HLTH-2024-DISEASE-13-01: Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)

[Watch Presentation](#) of Topic; [Watch the Q&A](#) on this Topic

Question	Link to answer
1. The allocated budget is 20,000,000 € for five proposals. Does this imply that each proposal is allocated 4,000,000 €? Is this correct?	23:51
2. Is it appropriate to create a multifunctional intervention program for sick children that develops Spiritual Intelligence integrating with medical help?	25:00
3. Would an intervention in LMICs, such as North Mazedonia, Serbia and Georgia, plus a comparative study in NZ with indigenous people be reasonable?	26:02
4. What are the conditions for having India as a partner country? Are there specific co-funding opportunities available for India?	27:11
5. Could you please indicate what can be considered a disadvantaged population, specifically in HICs?	28:41
6. Medication issues and mental health is quite prominently mentioned in the topic. So, a focus on this is reasonable, right?	29:29
7. Is there a list of non-communicable disease which should not be considered?	29:57
8. What kind of consortium are you looking for? How many partners and countries?	30:25
9. Would a proposal including an innovative technology for the management of long-term NCDs, be suitable for this call?	32:08
10. Is the UK already considered as third country? Could be included as regular partner in proposals?	32:43
11. Is it mandatory to include partners from LICs or MICs?	33:18
12. May it be better to focus on a specific region/sub-continent or to include multiple continents, i.e. LMIC + vulnerable populations in developed countries?	34:04
13. Could you deepen a little bit on the scope of the implementation research (size, significance...) compared with the limited pilot mentioned in the call?	34:53
14. Should a single intervention be chosen for all countries in the consortium or can different implementation strategies be considered for different interventions?	35:52
15. Maybe to mention here: USA entities are specifically eligible for this call.	36:30
16. Can people with mental health problems in HICs considered per se a disadvantaged population? Can this be justified?	37:46
17. Would a proposal focussing on endovascular treatment in minor stroke patients to diminish cognitive impairments be covered by this call?	38:28
18. The evidence of the intervention to be implemented, how robust has it to be? Could results from previous EU funded projects be used?	39:04
19. The systematic review mentioned in the call, should it be carried out during the project or should it be described in detail in the state of the art?	40:20
20. With the "pilot" I meant this: "a limited period of testing the effectiveness of an intervention adapted for local implem. is therefore usually appropriate"	41:00
21. What could be the weight of this part in relation with the overall project?	41:52

22. What is the max duration of the proposal?	42:25
23. Would you see implementation of home hospital services with patient data portability and data sovereignty suitable to this call?	43:37
24. A hybrid study is less likely to be funded?	45:09
25. Are applicants expected to provide a fully developed (clinical) research protocol for this call?	46:10

HORIZON-HLTH-2024-DISEASE-12-01: European partnership for pandemic preparedness

[Watch Presentation](#) of Topic; [Watch the Q&A](#) on this Topic

Question	Link to answer
1. How can I find partners or offer my organization as a partner?	02:01:58
2. Can academic entities be partners in the partnership? Maybe as affiliate?	02:03:08
3. Since there is a lot of research in the scope who should be a partner in this application.	02:04:39
4. What is the eligibility criteria to be a partner? How many partners will there be for each country?	02:05:09

[Destination 4. Ensuring access to innovative, sustainable and high-quality health care](#)

HORIZON-HLTH-2024-CARE-14-01: Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems (PCP)

[Watch PCP explanation](#) for Topic; [Watch Presentation](#) of Topic; [Watch the Q&A](#) on this Topic

Question	Link to answer
1. How many PCP projects do you wish to support?	01:29:23
2. How does the fast-track procedure work? (number of PCP phases, etc.)	01:29:51
3. Do the buyers (as public bodies) have to follow also the own/national rules for procurements in the development of PCP project?	01:30:32
4. What makes a PCP grant different from a RIA or an IA grant?	01:31:19
5. Can suppliers be part of the consortium for the PCP topic?	01:32:27
6. In addition to the funding rules of Horizon Europe what other rules should potential applicants of the PCP be aware of?	01:33:14
7. Can only public procurers cooperate with private ones in the area of health and care?	01:34:31
8. Is it possible to foresee budget in the proposal to purchase the solution in the case of FastTrack PCP?	01:34:31
9. How many buyers have to be present in the proposal, how many countries?	01:35:39
10. Budget balance between coordination and procurement budget? (50/50, undefined?)	01:36:20
11. What are the EC expectations in terms of commitment (last paragraphs of the call text): Declaration of interest: what does this mean? From whom?	01:37:20
12. Does the coordinator have to be a public body?	01:38:14
13. Would a proposal including an innovative technology for the management of long-term NCDs, be suitable for this call?	01:38:48

14. What are the EC expectations in terms of commitment (last paragraphs of the call text): Procurement of the solution as part of the PCP: is this budget eligible?	01:39:38
15. EC expectations of commitment regarding call text: Procurement of the solution as part of the PCP, would the market readability be also eligible?	01:40:05
16. EC expectations of commitment Procurement of the solution as part of the PCP: Deliverable prepares follow-up procurement. Is this the tender documents?	01:41:08
17. Due to implementation deadline restrictions, can we implement a pilot project (with a restricted n. of partners in the Healthcare sector)?	01:43:01

The concept and development process of this document belongs to the HNN3.0 network and is based on official information provided by European Commission experts during the HE 2024 Info Days.